Methyclothiazide (BioDeep_00000006596)

 

Secondary id: BioDeep_00000399173

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide

  化学式: C9H11Cl2N3O4S2 (358.9568)
中文名称: 甲乙噻嗪
  谱图信息: 最多检出来源 Homo sapiens(blood) 26.58%

分子结构信息

SMILES: CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O
InChI: InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)


描述信息

Methyclothiazide is only found in individuals that have used or taken this drug. It is a thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)Methyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
C - Cardiovascular system > C03 - Diuretics > C03A - Low-ceiling diuretics, thiazides > C03AA - Thiazides, plain
D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors
C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic
D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents
D049990 - Membrane Transport Modulators

同义名列表

82 个代谢物同义名

6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide; Methylchlorothiazide; Methylcyclothiazide; Methycyclothiazide; Methylclothiazide; Methychlothiazide; methyclothiazide; Methyclothiazid; Enduron; WLN: T66 BSWN EM DHJ C1 D1G HG ISZW; Methyclothiazide; (+-)-6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; (+/-)-6-CHLORO-3-(CHLOROMETHYL)-3,4-DIHYDRO-2-METHYL-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide, (-)-; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide, (+-)-; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide, (+)-; 2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE, 6-CHLORO-3-(CHLOROMETHYL)-3,4-DIHYDRO-2-METHYL-, 1,1-DIOXIDE, (+/-)-; 2H-1,2,4-Benzothiadiazine-7-sulfonamide,6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 2H-1,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 6-chloranyl-3-(chloromethyl)-2-methyl-1,1-bis(oxidanylidene)-3,4-dihydro-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide #; 6-Chloro-3-(chloromethyl)-3,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-chloromethyl-2-methyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3-chloromethyl-3,4-dihydro-2-methyl-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; Aquaresen; Aquatensen; Aquatensen;Enduron; C03AA08; DIUTENSEN-R COMPONENT METHYCLOTHIAZIDE; Duretic; Enduron (TN); Enduronum; ENDURONYL COMPONENT METHYCLOTHIAZIDE; EUTRON COMPONENT METHYCLOTHIAZIDE; L3H46UAC61; Methyclothiazide (JAN/USP/INN); METHYCLOTHIAZIDE (MART.); Methyclothiazide (Standard); Methyclothiazide (USAN:USP:INN:BAN:JAN); METHYCLOTHIAZIDE (USP MONOGRAPH); METHYCLOTHIAZIDE (USP-RS); METHYCLOTHIAZIDE [HSDB]; METHYCLOTHIAZIDE [INN]; METHYCLOTHIAZIDE [JAN]; METHYCLOTHIAZIDE [MART.]; METHYCLOTHIAZIDE [MI]; METHYCLOTHIAZIDE [ORANGE BOOK]; Methyclothiazide [USAN:USP:INN:BAN:JAN]; METHYCLOTHIAZIDE [USAN]; METHYCLOTHIAZIDE [USP MONOGRAPH]; METHYCLOTHIAZIDE [USP-RS]; METHYCLOTHIAZIDE [VANDF]; METHYCLOTHIAZIDE [WHO-DD]; METHYCLOTHIAZIDE COMPONENT OF DIUTENSEN-R; METHYCLOTHIAZIDE COMPONENT OF ENDURONYL; METHYCLOTHIAZIDE COMPONENT OF EUTRON; Methyclothiazide, (-)-; Methyclothiazide, (+)-; Methyclothiazidum; Methyclothiazidum (INN-Latin); Methyclothiazidum [INN-Latin]; Meticlotiazida; Meticlotiazida (INN-Spanish); Meticlotiazida [INN-Spanish]; Meticlotiazide; Meticlotiazide [DCIT]; Naturon (VAN); R00UUL4SRN; R6KDH2S0SX; Tox21_112450; Tox21_112450_1; UNII-L3H46UAC61; UNII-R00UUL4SRN; UNII-R6KDH2S0SX



数据库引用编号

19 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome()

BioCyc()

PlantCyc()

代谢反应

个相关的代谢反应过程信息。

Reactome()

BioCyc()

WikiPathways()

Plant Reactome()

INOH()

PlantCyc()

COVID-19 Disease Map()

PathBank()

PharmGKB()

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • H R Black, S G Chrysant, C L Curry, W H Frishman, R H Grimm, K C Lasseter, R Okun, J L Pool, V Raizada, N D Vlachakis. Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. Journal of clinical pharmacology. 1992 Apr; 32(4):351-9. doi: 10.1002/j.1552-4604.1992.tb03847.x. [PMID: 1349028]
  • R R Luther, H N Glassman, C B Estep, C J Maurath, D C Jordan. The effects of terazosin and methyclothiazide on blood pressure and serum lipids. American heart journal. 1989 Apr; 117(4):842-7. doi: 10.1016/0002-8703(89)90621-2. [PMID: 2564723]
  • M Labeeuw, N Pozet, A H Aissa, P Y Zech, J Sassard, M Laville. Uric acid renal handling: spontaneous changes and influence of a thiazide alone or associated with triamterene. International journal of clinical pharmacology, therapy, and toxicology. 1988 Feb; 26(2):79-83. doi: . [PMID: 3410590]
  • C Ferrier, C Beretta-Piccoli, P Weidmann, R Mordasini. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension. Clinical pharmacology and therapeutics. 1986 Nov; 40(5):525-30. doi: 10.1038/clpt.1986.218. [PMID: 2876796]
  • V S Wayne, J R Stockigt, G L Jennings. Treatment of mineralocorticoid-resistant renal hyperkalemia with hypertension (type II pseudohypoaldosteronism). Australian and New Zealand journal of medicine. 1986 Apr; 16(2):221-3. doi: 10.1111/j.1445-5994.1986.tb01154.x. [PMID: 3463275]
  • M Labeeuw, N Pozet, A Hadj Aissa, M P Minuit, J Sassard, P Zech. Renal handling of uric acid under methyclothiazide alone or associated with triamterene. Advances in experimental medicine and biology. 1986; 195 Pt A(?):365-9. doi: 10.1007/978-1-4684-5104-7_62. [PMID: 3728168]
  • P Jungers, B Lacour, J Daniel, P Chauveau, M Bruneau, M Bailly. [Comparative variations in natriuresis and urinary calcium in patients with hypercalciuric lithiasis treated with thiazide diuretics]. Nephrologie. 1984; 5(5):202-4. doi: NULL. [PMID: 6531057]
  • C A Hartman, N Kucharczyk, R D Sofia, J L Perhach. Determination of methyclothiazide in human plasma by high-performance liquid chromatography. Journal of chromatography. 1981 Dec; 226(2):510-3. doi: 10.1016/s0378-4347(00)86090-9. [PMID: 7320181]
  • E Desaulles, J Schwartz. A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin. British journal of pharmacology. 1979 Feb; 65(2):193-6. doi: 10.1111/j.1476-5381.1979.tb07818.x. [PMID: 760897]
  • R D Gordon, R H Mortimer, N Saar. Failure of methyclothiazide to lower home blood pressure level in "essential" hypertensive and normotensive young men, despite significant plasma volume contraction. European journal of clinical pharmacology. 1977 Dec; 12(6):403-8. doi: 10.1007/bf00561058. [PMID: 598414]
  • R A Evans. A cheap oral therapy for Paget's disease of bone. Australian and New Zealand journal of medicine. 1977 Jun; 7(3):259-61. doi: 10.1111/j.1445-5994.1977.tb03682.x. [PMID: 269686]
  • R A Evans. A cheap oral therapy for Paget's disease of bone. Calcified tissue research. 1977 May; 22 Suppl(?):287-91. doi: 10.1007/bf02064081. [PMID: 334345]
  • A M Parfitt. Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism. Annals of internal medicine. 1972 Oct; 77(4):557-63. doi: 10.7326/0003-4819-77-4-557. [PMID: 4642736]
  • A M Parfitt. The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism. The Journal of clinical investigation. 1972 Jul; 51(7):1879-88. doi: 10.1172/jci106990. [PMID: 4338123]
  • Y Suzuki, K Kojima, M Shinoda, I Yamagami. [Diuretics. 5. Effects of single or combined administration of diuretics in normal or spontaneously hypertensive rats]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1972 May; 68(3):276-89. doi: NULL. [PMID: 5066354]
  • R D Gordon, C G Pawsey, M W O'Halloran, M L Abbott, L L Wilson, H Silverstone. Use of home-blood-pressure measurement to compare the efficacy of two diuretics. Effects of methylclothiazide and frusemide on blood pressure and plasma renin activity and electrolytes. The Medical journal of Australia. 1971 Sep; 2(11):565-70. doi: 10.5694/j.1326-5377.1971.tb92410.x. [PMID: 5163370]
  • E V Mackay, S K Khoo, G Adsett, S Zymanska. A clinical study of the effects of an aldosterone antagonist (Aldactone-A) and a thiazide diuretic (Enduron) in pregnancy. The Australian & New Zealand journal of obstetrics & gynaecology. 1969 Aug; 9(3):188-95. doi: 10.1111/j.1479-828x.1969.tb02556.x. [PMID: 4900693]
  • A M Parfitt. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. The New England journal of medicine. 1969 Jul; 281(2):55-9. doi: 10.1056/nejm196907102810201. [PMID: 5305802]
  • E V Mackay, S K Khoo. Clinical and laboratory study of a new diuretic agent ('vectren') in pregnancy: a comparison with a diuretic agent in current use ('enduron'). The Medical journal of Australia. 1969 Mar; 1(12):607-12. doi: 10.5694/j.1326-5377.1969.tb92339.x. [PMID: 4889612]
  • V B Pilsbury, J V Jackson. Identification of the thiazide diuretic drugs. The Journal of pharmacy and pharmacology. 1966 Nov; 18(11):713-20. doi: 10.1111/j.2042-7158.1966.tb07792.x. [PMID: 4382047]
  • S G Sheps, P J Osmundson, J F Fairbairn, A Schirger, G J Kavanaugh, M K Burbank. Experience with guanoxan in the treatment of hypertension. Mayo Clinic proceedings. 1966 Sep; 41(9):577-84. doi: NULL. [PMID: 5918661]
  • P J POLLACK. PARGYLINE HYDROCHLORIDE AND METHYCLOTHIAZIDE COMBINED IN THE TREATMENT OF HYPERTENSION. Current therapeutic research, clinical and experimental. 1965 Jan; 7(?):10-8. doi: NULL. [PMID: 14246362]
  • M P SAMBHI, E H VENNING, J C BECK. ALDOSTERONE SECRETION RATE AND ELECTROLYTE BALANCE STUDIES ON THREE PATIENTS WITH HYPERTENSION. INFLUENCE OF GUANETHIDINE, HYDRALAZINE AND METHYCLOTHIAZIDE. Metabolism: clinical and experimental. 1964 Mar; 13(?):212-20. doi: 10.1016/0026-0495(64)90100-3. [PMID: 14127688]
  • K E ROBERTS. SULFONAMYL DIURETICS--MECHANISM OF ACTION AND THERAPEUTIC USE. California medicine. 1964 Mar; 100(?):160-4. doi: NULL. [PMID: 14131396]
  • A TOKUDA, M HOTTA, N OKAMOTO, C TAKEDA, T ISOBE, S YASUI. [CLINIC TRIAL OF METHYCLOTHIAZIDE (ENDURON)]. [Chiryo] [Therapy]. 1963; 45(?):2271-5. doi: NULL. [PMID: 14103597]